Investment Summary |
|
|---|---|
| Date | 2020-01-30 |
| Target | Arcutis |
| Sector | Life Science |
| Sellers(s) |
Frazier Healthcare Partners
HBM Partners OrbiMed Advisors |
| Deal Type | IPO |
SEARCH BY
| Category | Growth Capital Firm |
|---|---|
| Founded | 1991 |
| PE ASSETS | 3.4B USD |
| Size | Large |
| Type | Sector Focused |
Frazier Healthcare Partners is a private equity and venture capital firm specializing in Growth buyout investment specifically targets businesses that deal Healthcare, Life Sciences, Pharmaceutical services, medical products, and related sectors. Frazier Healthcare Partners was formed in 1991 and is based in Seattle, Washington with an additional office in Palo Alto, California; Boston, Massachusetts; and Menlo Park, California.
| DEAL STATS | # |
|---|---|
| Overall | 17 of 29 |
| Sector: Life Science M&A | 4 of 10 |
| Type: IPO M&A Deals | 2 of 5 |
| State: California M&A | 6 of 9 |
| Country: United States M&A | 17 of 29 |
| Year: 2020 M&A | 1 of 3 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2020-01-24 |
Eptam Precision Solutions
Northfield, New Hampshire, United States Eptam Plastics, Inc. is a provider of a comprehensive suite of machining and injection molding solutions through three manufacturing centers of excellence in Colorado, New Jersey, and New Hampshire. Eptam Plastics was founded in 1981 and is based in Northfield, New Hampshire. |
Buy | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2020-02-27 |
Passage Bio
Philadelphia, Pennsylvania, United States Passage Bio is a fully-integrated genetic medicines company developing life-transforming AAV-delivered in vivo therapeutics for the treatment of rare CNS diseases. Passage Bio was founded in 2018 and is based in Philadelphia, Pennsylvania. |
Sell | - |
| Category | Private Equity Firm |
|---|---|
| Founded | 2001 |
| PE ASSETS | 2.1B USD |
| Size | Large |
| Type | Sector Focused |
HBM Partners is a private investment firm focused on investing in entrepreneurial biopharma and other healthcare-related companies in Europe, North America, India and other Emerging Markets. HBM looks to invest $5 to $50 million per transaction and will consider private and public companies. HBM Partners was established in 2001 and is headquartered in Zug, Switzerland.
| DEAL STATS | # |
|---|---|
| Overall | 10 of 38 |
| Sector: Life Science M&A | 10 of 34 |
| Type: IPO M&A Deals | 10 of 29 |
| State: California M&A | 1 of 9 |
| Country: United States M&A | 8 of 27 |
| Year: 2020 M&A | 1 of 9 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2019-11-07 |
Galera Therapeutics
Malvern, Pennsylvania, United States Galera Therapeutics develops novel therapeutics that reduce severe side effects of radiation therapy in cancer patients. The lead molecule GC4419 has demonstrated efficacy in a phase IIb study in patients with head and neck cancer and has been granted Fast Track and Breakthrough Therapy designations by the U.S. FDA. Galera Therapeutics was founded in 2012 and is based in Malvern, Pennsylvania. |
Sell | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2020-02-12 |
ALX Oncology
San Francisco, California, United States ALX Oncology is a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint mechanism, which is exploited by cancer cells to evade the immune system. ALX Oncology was formed in 2015 and is based in San Francisco, California. |
Buy | - |
| Category | Private Equity Firm |
|---|---|
| Founded | 1989 |
| PE ASSETS | 14.0B USD |
| Size | Large |
| Type | Sector Focused |
OrbiMed Advisors is a global healthcare centric investment firm that invests in medical device, life science, healthcare service, and medical diagnostic companies. OrbiMed maintains three investment disciplines including Public Equity, Private Equity, and Royalty Opportunities. OrbiMed's Public Equity group manages a series of public equity funds, including long/short event-driven funds and closed-end investment trusts that invests across all types of publicly-traded companies, from biopharmaceuticals to medical devices and healthcare services worldwide. OrbiMed's Private Equity group invests in start-ups through growth equity financings. OrbiMed prefers to be the lead investor and will consider opportunities across North America, Asia, Europe and Israel. OrbiMed's Royalty practice provides commercial-stage healthcare companies with non-dilutive structured debt capital. OrbiMed was formed in 1989 and is based in New York City.
| DEAL STATS | # |
|---|---|
| Overall | 4 of 4 |
| Sector: Life Science M&A | 3 of 3 |
| Type: IPO M&A Deals | 2 of 2 |
| State: California M&A | 2 of 2 |
| Country: United States M&A | 3 of 3 |
| Year: 2020 M&A | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2018-09-26 |
GENEWIZ
South Plainfield, New Jersey, United States GENEWIZ, Inc. is a provider of R&D genomics services that enable research scientists within pharmaceutical, biotechnology, agriculture, environmental and clean energy, academic, and government institutions to advance their discoveries. GENEWIZ, Inc. was founded in 1999 and is based in South Plainfield, New Jersey. |
Sell | $450M |
